The use of a laser and pilocarpine in improving saliva secretion in patients with head and neck cancer who have undergone radiochemotherapy

Not Applicable

• Conditions: Patients with head and neck cancer and radiochemotherapy; Cancer

• Registration Number: ISRCTN56133161
• Lead Sponsor: Damascus University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-08-21
• Last Update Posted: 4 September 2023
• Study Completion: 2024-07-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. The minimum radiation dose to which the patient is exposed is 50 Gy
2. Radiation should be at least above the parotid gland and the submandibular gland on both sides
3. The patients are 18 years old or over
4. The patients did not undergo radiotherapy before
5. The patients did not undergo chemotherapy for at least the past two months
6. Karnofsky performance scale above 60

Exclusion Criteria

1. Sjogren's syndrome, diabetes and autoimmune diseases
2. Clinically significant uncontrolled cardiac, renal, pulmonary, visual problems or other chronic diseases that could potentially interfere with the evaluation of the safety and efficacy of pilocarpine
3. Tricyclic antidepressants, antihistamines with anticholinergic effects or Beta-blockers
4. Pilocarpine for ophthalmic indications was also excluded from the study
5. Tumor located in the parotid gland, submandibular gland, the blood or the floor of the mouth

Study & Design

• Study Type: Interventional
• Study Design: Not specified